• Users Online: 143
  • Print this page
  • Email this page
Year : 2022  |  Volume : 13  |  Issue : 4  |  Page : 377-384

Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience

1 Lina Diabetes Center, Mumbai, Maharashtra, India
2 Department of Endocrinology, KPC Medical College, Kolkata, India
3 Consultant Endocrinologist and Diabetologist, Apollo Sugar Clinics, Kolkata, West Bengal, India

Correspondence Address:
Dr. Supratik C Bhattacharyya
Consultant Endocrinologist and Diabetologist, Apollo Sugar Clinics, Kolkata 700064, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jod.jod_71_22

Rights and Permissions

A long-acting oral glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide is a new armamentarium to glycemic treatments. The Peptide Innovation for Early Diabetes Treatment (PIONEER) 3, 4, 5, 6, and 10 provided the necessary evidence on the efficacy of semaglutide in type 2 diabetes. The American Diabetes Association considers GLP-1 receptor agonists and insulin a high glycemic efficacy therapy. Further, a GLP-1 receptor agonist is recommended when there is a need for minimizing weight gain or promoting weight loss. There are no reports or clinical trials on oral semaglutide in Indian subjects with type 2 diabetes. We present seven case reports where semaglutide was initiated with other antidiabetic medications to bring the glycated hemoglobin (HbA1c) under target and promote weight loss. Between 45 days and 60 days of treatment with antidiabetic drugs, including semaglutide, resulted in a 1.5% reduction in HbA1c. A reduction in body weight ranged from 1.7 kg to 10 kg. Large-scale randomized trial in Indian patients is warranted to confirm our findings.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded43    
    Comments [Add]    

Recommend this journal